Does Affinity Health Plan Cover Semaglutide (Wegovy)?

What Is Wegovy and Why Does Coverage Matter?

Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous GLP-1 receptor agonist approved by the FDA in June 2021 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. The medication works by mimicking glucagon-like peptide-1, suppressing appetite, slowing gastric emptying, and reducing caloric intake at a neurological level. Because the list price sits near $1,349 per month, insurance coverage is not a convenience. For most patients, it is the difference between access and none at all.

The clinical evidence supporting Wegovy is extensive. In the STEP-1 trial (N=1,961), once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% over 68 weeks compared with 2.4% for placebo (P<0.001), with 86.4% of participants achieving at least 5% weight loss [1]. The STEP-4 trial (N=803) showed that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within 48 weeks, underscoring the need for continued access [2]. Coverage gaps therefore carry direct clinical consequences.

The SELECT cardiovascular outcomes trial (N=17,604) further demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% vs. placebo in adults with overweight or obesity and established cardiovascular disease, without a diabetes diagnosis [3]. That finding shifted the clinical framing of Wegovy from a cosmetic weight-loss drug to a cardioprotective therapy, and it strengthens the medical-necessity argument for payers including Affinity Health Plan.

For context on national obesity burden, the CDC estimates that 41.9% of U.S. adults had obesity as of the 2017-2020 NHANES cycle [4]. The American Heart Association and American College of Cardiology classify obesity as a major modifiable cardiovascular risk factor in their 2023 guidelines [5].

How Affinity Health Plan Structures Its Drug Formulary

Affinity Health Plan is a New York-based managed-care organization that operates Medicaid managed care, Child Health Plus, and Essential Plan products primarily in the New York metropolitan area. Its formulary is governed by New York State Medicaid rules, federal Medicaid law, and the plan's own pharmacy and therapeutics (P&T) committee decisions.

GLP-1 receptor agonists for weight management occupy a complicated tier in most Medicaid-aligned formularies. New York State Medicaid has historically covered anti-obesity medications with restrictions, and Affinity's coverage mirrors that framework. The FDA-approved indication for Wegovy under ICD-10 code E66 (obesity) is the primary clinical anchor for any coverage determination.

The Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy states that "pharmacological treatment of obesity should be used as an adjunct to lifestyle modifications" and that treatment is indicated for patients with a BMI of 30 or a BMI of 27 with weight-related comorbidities [6]. Affinity Health Plan's medical necessity criteria for anti-obesity medications typically align closely with this guidance, meaning prescribers who frame the clinical case using Endocrine Society language have a stronger authorization base.

The FDA label for Wegovy itself specifies use "as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition" [7]. Any prior authorization submission that references this labeling language directly is better positioned for approval.

Drugs on Medicaid formularies are subject to CMS best-price and rebate rules. Under the Inflation Reduction Act and subsequent CMS guidance, states retain flexibility to impose prior authorization for anti-obesity medications [8]. That flexibility is why coverage is not automatic even when the clinical evidence is strong.

Does Affinity Health Plan Actually Cover Semaglutide (Wegovy)?

Affinity Health Plan may cover Wegovy for members who satisfy documented clinical criteria. Coverage is not guaranteed and depends on the specific product line (Medicaid managed care vs. Essential Plan vs. commercial), the prescribing provider's participation status, and the completeness of the prior authorization packet.

For Medicaid managed-care members, New York State Medicaid's fee-for-service program provides a useful benchmark. New York Medicaid covers anti-obesity pharmacotherapy when the prescriber documents BMI at or above threshold, a comorbid condition where applicable, and participation in or referral to a structured weight-management program. Affinity's managed-care policies generally follow these state standards. The key phrase in most Affinity authorization criteria mirrors CMS guidance: the medication must be used "as an adjunct to a reduced-calorie diet and increased physical activity" [8].

For Essential Plan members, coverage of weight-management medications has expanded in recent years as New York State updated its Essential Plan benefit package to align more closely with Qualified Health Plan standards. However, Wegovy's inclusion in that formulary tier remains subject to P&T committee review cycles, and members should verify current formulary status directly with Affinity at the time of prescribing.

Commercial or employer-sponsored plans administered by Affinity follow their own benefit documents. The Affordable Care Act does not mandate coverage of anti-obesity drugs, so commercial plan coverage varies by employer contract. Some employer groups explicitly carve out weight-loss medications; others include them with prior authorization. Confirming the specific benefit document is the only reliable way to know.

The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines for obesity recommend semaglutide as a first-line pharmacotherapy option given its efficacy and cardiovascular outcome data [9]. Citing AACE 2022 in a prior authorization letter gives the submission guideline-level backing.

Prior Authorization Requirements: What Prescribers Must Submit

Prior authorization for Wegovy through Affinity Health Plan typically requires the following documentation, based on standard Medicaid managed-care criteria and the FDA label.

First, the prescriber must document the member's current BMI using an in-person or telehealth visit measurement, not a self-reported value. A BMI of 30 or higher satisfies the obesity threshold. A BMI of 27 or higher requires at least one qualifying comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Second, the prescriber must document that the patient has attempted a structured behavioral or dietary intervention. This does not have to be a formal 16-session intensive behavioral therapy program, though the U.S. Preventive Services Task Force (USPSTF) 2018 recommendation on weight loss to prevent obesity-related morbidity does recommend offering or referring adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions [10]. Citing USPSTF support for structured intervention strengthens the authorization.

Third, the prescriber must demonstrate that contraindications are absent. Wegovy carries a boxed warning for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7]. Documenting the absence of these contraindications in the chart is mandatory.

Fourth, the authorization must specify the intended dose titration schedule. The FDA-approved titration for Wegovy starts at 0.25 mg once weekly for 4 weeks, escalates every 4 weeks, and reaches the maintenance dose of 2.4 mg at week 17 [7]. Payers may deny a request that does not specify this schedule because it signals incomplete clinical planning.

The table below summarizes the standard documentation framework for a Wegovy prior authorization submission targeted at Medicaid-aligned plans like Affinity.

PA Documentation Checklist:

• Current BMI with measurement date and method
• ICD-10 code E66.01 (morbid obesity) or E66.09 (other obesity) or E66.9 (obesity, unspecified)
• Comorbidity code(s) if BMI is 27-29.9 (e.g., E11.9 for type 2 diabetes, I10 for hypertension)
• Documentation of prior behavioral/dietary intervention attempt (dates, program name or provider)
• Absence of contraindications (thyroid cancer history, MEN 2)
• Dose titration schedule following FDA label
• Prescriber NPI and DEA number
• Reference to AACE 2022 or Endocrine Society 2015 guideline recommendation

Plans typically respond within 3 business days for non-urgent requests and 72 hours for urgent requests, per CMS managed-care timeliness standards [8].

What Happens If Affinity Denies the Prior Authorization?

A denial is not the end of the road. Federal Medicaid regulations and New York State managed-care rules require Affinity to provide a written denial with a specific clinical rationale and information about appeal rights. Members have the right to request a standard appeal within 60 days of the denial notice and an expedited appeal within 72 hours if the standard timeline would seriously jeopardize health.

If the internal appeal fails, the member can request an external appeal through the New York State Department of Financial Services (DFS) or the New York State Department of Health (DOH) Independent Review Organization process. External appeals for medications with strong guideline support, such as Wegovy, succeed at meaningful rates when the clinical record is complete.

The STEP-1 trial data are directly useful in appeal letters. The 14.9% mean weight loss at 68 weeks (P<0.001) and the 86.4% rate of achieving at least 5% weight loss [1] provide statistical grounding. For patients with cardiovascular disease, the SELECT trial's 20% MACE reduction [3] reframes the medication as a cardiovascular therapy rather than a weight-loss drug, which may shift the payer's clinical calculus.

A direct quotation from the AACE 2022 guideline supports the appeal: "Pharmacotherapy for obesity, as an adjunct to lifestyle therapy, should be offered to patients with a BMI of 30 or greater, or a BMI of 27 or greater with a weight-related comorbidity, if lifestyle therapy alone has not achieved clinically meaningful weight loss" [9]. This language maps directly onto most plan medical-necessity criteria.

Patients who are denied and cannot wait for an appeal cycle may access the Novo Nordisk savings card program. Commercially insured patients who are not covered by a government program may pay as low as $25 per month for up to 24 months through the manufacturer's patient savings program. Patients without any insurance may qualify for the Novo Nordisk Patient Assistance Program, which provides Wegovy at no cost to eligible low-income patients.

The Clinical Case for Coverage: Obesity as a Disease

One of the most effective reframing strategies for both prior authorizations and appeals is positioning obesity as a chronic disease rather than a lifestyle choice. This framing has strong guideline support. The American Medical Association recognized obesity as a disease in 2013. The World Health Organization classifies obesity under ICD-10 code E66, designating it as a chronic non-communicable disease with multifactorial etiology [11].

The NEJM Perspective by Bray et al. (2017) articulated that obesity is driven by genetic, neurobiological, and environmental factors that resist purely behavioral intervention [12]. Semaglutide's mechanism of action directly addresses the neurobiological component by acting on GLP-1 receptors in the hypothalamus to reduce hunger signals, a pharmacological target that dietary changes alone cannot replicate [13].

The STEP-5 trial (N=304) demonstrated that semaglutide 2.4 mg maintained 15.2% weight loss over 104 weeks (2 years), confirming durability of effect with continued use [14]. This two-year efficacy data is relevant for payers who question whether continued coverage is warranted after the first year.

For patients with type 2 diabetes who are being considered for Ozempic (semaglutide 1.0 mg) rather than Wegovy, the SUSTAIN-6 trial (N=3,297) showed a 26% reduction in MACE vs. placebo (P<0.001 for non-inferiority, P=0.02 for superiority) [15]. Ozempic carries a different FDA indication (type 2 diabetes management) and different formulary placement than Wegovy, and coverage pathways differ accordingly.

The distinction matters clinically and administratively. A patient with type 2 diabetes and obesity may qualify for semaglutide coverage through either the diabetes indication (Ozempic or Rybelsus) or the obesity indication (Wegovy), depending on which pathway the prescriber pursues and which formulary tier offers better access.

Cost and Access Alternatives When Coverage Is Denied

When Affinity Health Plan denies coverage and appeals are exhausted or time-sensitive, several alternatives exist.

The Novo Nordisk NovoCare patient assistance program accepts applications from patients with household incomes at or below 400% of the federal poverty level who lack adequate insurance coverage [7]. Applications require prescriber involvement and income documentation.

Compounded semaglutide was widely available from 503A and 503B pharmacies between 2022 and 2024 when Wegovy was on the FDA drug shortage list. The FDA removed semaglutide injection from the shortage list in February 2024, which means 503B outsourcing facilities are no longer permitted to compound copies of FDA-approved semaglutide products, though some 503A compounding pharmacies continue under individualized patient prescriptions [16]. Prescribers and patients should verify current FDA enforcement posture before pursuing compounded semaglutide.

Tirzepatide (Zepbound), FDA-approved for obesity in November 2023, achieved 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose [17]. Some plans that deny Wegovy may have different formulary placement for tirzepatide, and a step-therapy approach starting with tirzepatide may be clinically equivalent or superior for some patients.

The FDA's Orange Book lists Wegovy's NDA number as 215256, useful when submitting appeals that reference the regulatory approval basis [16]. Referencing the specific NDA in an appeal letter signals clinical sophistication and reduces the payer's ability to dismiss the request on procedural grounds.

For members appealing a denial, the New York State Medicaid managed-care model contract requires Affinity to cover a continuation of the previously authorized medication during the appeal period if the denial is based on a formulary change rather than a new request [8]. Members who had prior coverage should request this continuation explicitly.

What to Tell Your Doctor Before Submitting to Affinity

The prescriber controls most of the variables that determine authorization success. Patients who understand what documentation strengthens their case can advocate more effectively at the point of care.

Ask the prescriber to record BMI in the visit note using an objective measurement, not a historical value from a prior visit. A BMI reading from the day of the prescription carries more weight in a PA review than one from six months prior.

Ask the prescriber to document comorbidities explicitly rather than listing them in the problem list without connecting them to the obesity diagnosis. A note that reads "BMI 29.4 with hypertension (I10), dyslipidemia (E78.5), and obstructive sleep apnea (G47.33) in the context of obesity (E66.09), qualifying for Wegovy per FDA label and AACE 2022 guideline criteria" is far more defensible than a generic obesity code.

Ask the prescriber to include a brief narrative about prior weight-management attempts. Even a 3-month trial of a structured dietary approach with documented weight outcomes counts as prior therapy. The USPSTF recommends offering intensive behavioral counseling, so documenting referral to or participation in such a program directly satisfies that criterion [10].

Ask about the dose titration plan. A prescriber who documents a specific 17-week titration schedule aligned with the FDA label signals to the payer that the prescription is being managed according to approved protocols [7].

Finally, confirm that the prescriber's NPI is credentialed with Affinity Health Plan before the prescription is submitted. An out-of-network prescriber may not be able to submit a PA directly, creating an administrative barrier that delays access independent of clinical merit.

The STEP-2 trial (N=1,210) demonstrated that semaglutide 2.4 mg produced 9.6% weight loss in patients with type 2 diabetes at 68 weeks vs. 3.4% for placebo (P<0.001) [18], a finding directly relevant for Affinity members whose primary diagnosis is diabetes rather than obesity. Including this citation in a PA for a diabetic patient with obesity strengthens the argument that the medication serves dual therapeutic purposes.

Affinity Health Plan members who have not yet tried the medication but are considering it should request a benefits verification call with the Affinity pharmacy department before the prescription is written. This step takes 10 to 15 minutes and can confirm current formulary tier, PA requirements, and copay structure. Starting that call with the drug name, NDC code, and the member's specific plan ID significantly reduces the chance of receiving generic information that does not apply to the member's product.